What’s new


The fourth Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI) was held on 1 December 2015 in Capetown, South Africa. All members (bar 1) of the CG, attended the meeting, along with observers from the Global Laboratory Initiative (GLI), Global TB Drugs Facility (GDF), Global Fund (GF), USAID, and Leaders of the GDI Task Force on "Access to new DR-TB drugs.

The objectives of the meeting were:

  • To follow up on recommendations made and action points agreed upon during 3rd GDI CG meeting in May 2015, and subsequent monthly teleconferences;
  • To provide an update on progress in scale up of MDR-TB services and care, and updates on new policies;
  • To provide an update on the Joint GDI and GLI Partners Forum, April 2015;
  • To provide an update on the progress of the respective GDI Task Forces and from the Infection Control (IC) sub-group; and
  • To discuss the GDI CG membership, the GDI "Costed Framework Plan, 2016-2017" and the GDI workplan for 2016.

The participants were briefed about the activities of the GDI Secretariat since the third CG meeting held in May 2015. An update was provided to the CG on "progress in scale-up MDR-TB services and care, and on new policies". This was followed by a "Joint update from the GDI and the GLI" at which the members of the GLI Core Group were present for the update and subsequent discussions. The respective GDI Task Forces and the TB Infection Control sub-group presented the progress and the activities in their respective areas to the GDI CG. A final session then discussed the "GDI CG membership, the GDI Costed Framework Plan 2016-17, GDI funding and workplan for 2016".

All meeting documents can be found at the " Meetings" tab."

The third Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI) was held on 1 May 2015 in Geneva, Switzerland. All members of the CG, attended the meeting, along with observers from the Global Laboratory Initiative (GLI), Global TB Drugs Facility (GDF), Global Fund (GF), Infection Prevention and Control (IC) sub-group and the USAID.

The objectives of the meeting were:

  • To follow up on recommendations from the GDI/GLI forum, including the issue of the "call to action on the introduction of new anti-TB drugs"
  • To follow up on recommendations and action points agreed upon during 2nd GDI CG meeting and subsequent monthly teleconferences
  • To provide an update on the progress of the GDI Task Forces, and the Infection Control (IC) sub-group
  • To review the strategic priorities of GDI and plan subsequent activities for the next year; and
  • To discuss the GDI "costed framework" and the work plan

The participants were briefed about the activities of the GDI Secretariat since the second CG meeting held in October 2014.

Following discussions between the GDI CG members and interested participants from the Joint GDI/GLI Partners Forum, there was general consensus that no-one wanted any "new" structures outside of considering a new Task Force. Hence GDI CG agreed that the creation of a GDI Task Force to address this issue was the best solution.

A joint session of the GDI and GLI CGs discussed the issue of growing gaps between the number of MDR-TB cases detected and the numbers started on treatment. GDI and GLI chairs also reviewed the recommendations from the previous joint meeting, as well as relevant issues raised during the Joint GDI/GLI partners forum.

All meeting documents can be found at the ‘Meetings’ tab.

Professor Charles Daley, MD, elected as Chair of the Core Group of Global Drug-resistant TB Initiative (GDI)

Professor Charles Daley, MD, was elected as the Chair of Core Group of the Global Drug-resistant TB Initiative (GDI) by the Core Group members. Dr Daley has served till recently as the Chair of the global Green Light Committee (gGLC) and brings with him strong clinical and educational background, field experience, leadership, and the ability to bring people together for global scale up of the programmatic management of drug-resistant TB (PMDT).

Dr Daley has worked with drug resistant tuberculosis patients for 20 years. He developed and implemented a national tuberculosis advice line that helped TB programs across the United States manage complicated forms of tuberculosis, including drug-resistant tuberculosis (DR-TB). He participated in the development of the WHO 2008 Emergency Update of the Guidelines for the Programmatic Management of Drug-resistant Tuberculosis as well as the 2011 updates to the PMDT guidelines. Over the past few years, he has provided monitoring and technical assistance support to several high TB/ MDR-TB burden countries including China, the Philippines, Peru, and Kyrgyzstan. He has facilitated several international PMDT trainings aimed at building capacity for scale-up of PMDT. He has also conducted research in countries such as Tanzania, Uganda, Brazil, and Colombia.

Announcing selection of Core Group of the Global Drug-resistant TB Initiative

Background

Drug-resistant tuberculosis (DR-TB), particularly multi-drug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) represent significant threats to global TB control efforts and a major public health concern in several countries. Levels of MDR-TB remain worryingly high in some parts of the world, notably countries in Eastern Europe and Central Asia. In several of these countries, up to 32% of new cases and more than 50% of previously treated cases have MDR-TB.

The World Health Organization (WHO) estimates that worldwide 450,000 people developed multi-drug resistant TB (MDR-TB) and at least 170,000 deaths were caused by MDR-TB in 2012. Globally, the overall detection of cases of MDR-TB increased from 29,000 in 2008 to about 94,000 in 2012. However, only around 77,000 eligible patients were actually put on MDR-TB treatment. Despite progress, the number of MDR-TB cases initiated on proper treatment in 2012 represented only 17% of the estimated cases of MDR-TB. Achieving universal access to treatment as envisaged in resolution WHA62.15 requires a bold and concerted drive on many fronts of TB care.

The Global Drug-resistant TB Initiative (GDI) has been recently constituted as a Working Group for drug- resistant TB related issues (DR-TB) replacing the previous MDR-TB Working Group and the global Green Light Committee (gGLC). The main focus of the GDI will be accelerating the global response to DR-TB through a partnership approach with involvement of all key stakeholders.